Berman Howard's Form 4 filing
Coya Therapeutics, Inc. (COYA) · filed Jan 4, 2023
- Accession no.
- 0001493152-23-000227
- Filed
- Jan 4, 2023
- Trade date
- Jan 3, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001493152-23-001702 (Jan 17, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berman HowardCIK 0001952986 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +10,000 | –F1 | – | 10,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +5,000 | –F1 | – | 5,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.